Amedeo Smart

Free Medical Literature Service

 

Amedeo

Tuberculosis
  Free Subscription

Articles published in
Antimicrob Agents Chemother
    September 2026
  1. HO VQT, Fontaine V, Anoz-Carbonell E, Djaout K, et al
    Inhibition of type II NADH dehydrogenase in Mycobacterium tuberculosis reveals collateral vulnerability in the electron transport chain.
    Antimicrob Agents Chemother. 2026 Sep 24:e0075626. doi: 10.1128/aac.00756.
    >> Share

  2. VIA LE, Sarathy J, Weiner DM, Greenstein T, et al
    Efficacy of quabodepistat alone and in combination with delamanid and bedaquiline against Mycobacterium tuberculosis in an NHP model evaluated by [(18)F] FDG PET/CT and bacterial burden.
    Antimicrob Agents Chemother. 2026 Sep 16:e0028026. doi: 10.1128/aac.00280.
    >> Share

    August 2026
  3. ROSSOUW J, Wallis R, Kornfeld H, Singhal A, et al
    The effect of metformin on the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide in adults with tuberculosis.
    Antimicrob Agents Chemother. 2026 Aug 6:e0074826. doi: 10.1128/aac.00748.
    >> Share

    July 2026
  4. HENDRIX J, Al Mubarak R, Rossmassler K, Nielsen H, et al
    Adaptive immunity shapes baseline physiology of M. tuberculosis in high-dose versus low-dose infection BALB/c mouse drug treatment models.
    Antimicrob Agents Chemother. 2026 Jul 31:e0042126. doi: 10.1128/aac.00421.
    >> Share

  5. RABODOARIVELO MS, Galizia J, Recchia D, Stamilla A, et al
    In vitro characterization of GSK2556286 in combination with bedaquiline and pretomanid against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2026 Jul 13:e0026026. doi: 10.1128/aac.00260.
    >> Share

  6. BRUNING-BARRY R, Ambroso JL, Yang X, Hickman D, et al
    Safety evaluation of pretomanid, an anti-tuberculosis drug, for the treatment of pregnant and lactating women.
    Antimicrob Agents Chemother. 2026 Jul 10:e0034326. doi: 10.1128/aac.00343.
    >> Share

  7. CALDERIN JM, Wasserman S, Antilus-Sainte R, Cristaldo M, et al
    Central nervous system antituberculosis drug exposures in a rabbit model of tuberculous meningitis.
    Antimicrob Agents Chemother. 2026 Jul 10:e0026126. doi: 10.1128/aac.00261.
    >> Share

    June 2026
  8. CHEN X, Ruiz-Gonzalez CE, Masias-Leon Y, Singh M, et al
    Ethionamide versus ethambutol-containing first-line regimens for TB meningitis.
    Antimicrob Agents Chemother. 2026 Jun 15:e0019026. doi: 10.1128/aac.00190.
    >> Share

  9. KIKSTRA N, Beek SWv, Maartens G, Brust JCM, et al
    Bedaquiline reloading strategies following interruptions during daily dosing.
    Antimicrob Agents Chemother. 2026;70:e0006326.
    >> Share

    May 2026
  10. YOON MH, Culviner PH, Pereira Moraes M, Nitta H, et al
    Strain diversity drives heterogeneous responses to tuberculosis combination therapy.
    Antimicrob Agents Chemother. 2026 May 15:e0184925. doi: 10.1128/aac.01849.
    >> Share

    April 2026
  11. CUMMINGS JE, Woolhiser LK, Guglielmi V, Romano A, et al
    Pretomanid vs delamanid in a bedaquiline-linezolid regimen: efficacy in a high-burden tuberculosis mouse model.
    Antimicrob Agents Chemother. 2026 Apr 29:e0195325. doi: 10.1128/aac.01953.
    >> Share

  12. KUTSCHER HL, Tamblin M, Kenney P, Reynolds JL, et al
    Weekly pulmonary delivery of beta-glucan-chitosan-poly(lactic co-glycolic) acid (beta-C-P) nanoparticles with daily standard oral therapy achieves control of Mycobacterium tuberculosis in BALB/c mice.
    Antimicrob Agents Chemother. 2026 Apr 20:e0028126. doi: 10.1128/aac.00281.
    >> Share

    March 2026
  13. ABDELWAHAB MT, Svensson EM, Diacon AH, Conradie A, et al
    Exposure-QTc modeling of bedaquiline, pretomanid, and clofazimine in adults with tuberculosis.
    Antimicrob Agents Chemother. 2026 Mar 9:e0139925. doi: 10.1128/aac.01399.
    >> Share

  14. MARANCHICK NF, Martyn-Dickens C, Enimil A, Yang H, et al
    Population pharmacokinetics of pyrazinamide and ethambutol in children with tuberculosis with or without HIV.
    Antimicrob Agents Chemother. 2026 Mar 2:e0090925. doi: 10.1128/aac.00909.
    >> Share

    February 2026
  15. LAMONT EA, Kordus SL, Howe MD, Jia Z, et al
    Essential role of MHC II in the antitubercular efficacy of pyrazinamide.
    Antimicrob Agents Chemother. 2026;70:e0126425.
    >> Share

    January 2026
  16. SORDELLO S, Brock L, Tagliavini A, Federico D, et al
    A modeling-based framework to evaluate forgiveness of tuberculosis treatment in a BALB/c relapsing mouse model.
    Antimicrob Agents Chemother. 2026 Jan 15:e0110925. doi: 10.1128/aac.01109.
    >> Share

  17. KUTSCHER HL, Tamblin M, Smith E, Shah A, et al
    Repeated pulmonary dosing of beta-glucan-chitosan-PLGA nanoparticles controls Mycobacterium tuberculosis in mice.
    Antimicrob Agents Chemother. 2026 Jan 14:e0148025. doi: 10.1128/aac.01480.
    >> Share

    December 2025
  18. CLARY J, Roberts JK, Hanna D, Tagliavini A, et al
    A stochastic simulation-based approach to inform the relapsing mouse model study design for non-clinical assessment of tuberculosis.
    Antimicrob Agents Chemother. 2025 Dec 29:e0110325. doi: 10.1128/aac.01103.
    >> Share

  19. UPTON CM, Calderin JM, Diacon AH, Boeree MJ, et al
    Cerebrospinal fluid penetration of cycloserine/terizidone and clofazimine in patients with pulmonary TB.
    Antimicrob Agents Chemother. 2025;69:e0093125.
    >> Share

    October 2025
  20. MARCH VFA, Zwyer M, Loiseau C, Brites D, et al
    Variability in intrinsic drug tolerance in Mycobacterium tuberculosis corresponds with phylogenetic lineage.
    Antimicrob Agents Chemother. 2025 Oct 21:e0099625. doi: 10.1128/aac.00996.
    >> Share

    September 2025
  21. PEROUTKA-BIGUS N, Scherman MS, Kaya F, Waidyarachchi SL, et al
    Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosis.
    Antimicrob Agents Chemother. 2025 Sep 30:e0118325. doi: 10.1128/aac.01183.
    >> Share

  22. SINGH S, Devine M, Gumbo T, Srivastava S, et al
    Epetraborole pharmacokinetics/pharmacodynamics in the hollow fiber system model of Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2025 Sep 22:e0048125. doi: 10.1128/aac.00481.
    >> Share

  23. RUPASINGHE P, Ismail N, Mulders W, Warren RM, et al
    In vitro exposure to clofazimine can select for delamanid and pretomanid resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2025 Sep 22:e0111325. doi: 10.1128/aac.01113.
    >> Share

  24. BALDIN VP, Harding CL, Quach D, Sugie J, et al
    Thienopyrimidine amide analogs target MmpL3 in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2025 Sep 22:e0098025. doi: 10.1128/aac.00980.
    >> Share

  25. WYNN EA, Dide-Agossou C, Al Mubarak R, Rossmassler K, et al
    Deconvoluting drug interactions using M. tuberculosis physiologic processes: transcriptional disaggregation of the BPaL regimen in vivo.
    Antimicrob Agents Chemother. 2025 Sep 18:e0049225. doi: 10.1128/aac.00492.
    >> Share

  26. KIRUBAKAR G, Johnston L, Nae Rin Lee B, Russell DG, et al
    Incorporation of macrophage immune stresses into an intracellular assay of drug tolerance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2025 Sep 11:e0079525. doi: 10.1128/aac.00795.
    >> Share

  27. RESENDIZ-GALVAN JE, Arora PR, Lokhande RV, Udwadia ZF, et al
    Evaluation of cycloserine dose regimens in an Indian cohort with multidrug-resistant tuberculosis: a population pharmacokinetic analysis.
    Antimicrob Agents Chemother. 2025 Sep 2:e0010125. doi: 10.1128/aac.00101.
    >> Share

    August 2025
  28. ZHANG M, Allen R, Ames L, Engelhart CA, et al
    Microbiological evidence for the trisubstituted benzimidazoles targeting MmpL3 in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2025 Aug 19:e0036825. doi: 10.1128/aac.00368.
    >> Share

  29. ISMAIL N, Sirgel F, Omar SV, Omar S, et al
    Unpacking bedaquiline heteroresistance: the importance of intermediate profiles for phenotypic drug susceptibility testing.
    Antimicrob Agents Chemother. 2025;69:e0035625.
    >> Share

    July 2025
  30. VAN SCHALKWYK M, Bekker A, Decloedt E, Wang J, et al
    Pharmacokinetics of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum with and without efavirenz-based antiretroviral treatment: IMPAACT P1026s study.
    Antimicrob Agents Chemother. 2025 Jul 31:e0005225. doi: 10.1128/aac.00052.
    >> Share

  31. LIANG L, Quigley J, Theriault M, Iinishi A, et al
    A chlorinated diketopiperazine antibiotic targets Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2025 Jul 31:e0036925. doi: 10.1128/aac.00369.
    >> Share

  32. CALDERIN JM, Wasserman S, Resendiz-Galvan JE, Abdelgawad N, et al
    Population pharmacokinetics of pyrazinamide and isoniazid in plasma and cerebrospinal fluid from South African adults with tuberculous meningitis.
    Antimicrob Agents Chemother. 2025 Jul 1:e0009925. doi: 10.1128/aac.00099.
    >> Share

    June 2025
  33. PEROUTKA-BIGUS N, Brooks EJ, Ramey ME, D'Erasmo H, et al
    Erratum for Peroutka-Bigus et al., "Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy- or hard-to-treat tuberculosis disease".
    Antimicrob Agents Chemother. 2025 Jun 26:e0065425. doi: 10.1128/aac.00654.
    >> Share

    May 2025
  34. ARMESILLA-DIAZ A, Pilar Arenaz M, Ashby C, Blanco D, et al
    High-throughput screening of small molecules targeting Mycobacterium tuberculosis in human iPSC macrophages.
    Antimicrob Agents Chemother. 2025 May 27:e0161324. doi: 10.1128/aac.01613.
    >> Share

    April 2025
  35. SONI H, Tyagi S, Mane K, Shelke AM, et al
    The KasA inhibitor JSF-3285 improves the sterilizing activity of bedaquiline-pretomanid-containing regimens in a mouse model of tuberculosis.
    Antimicrob Agents Chemother. 2025 Apr 23:e0013025. doi: 10.1128/aac.00130.
    >> Share

  36. LI D, Li L, Zhang Y, Cheng K, et al
    Efficacy of novel regimens targeting oxidative phosphorylation in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2025 Apr 22:e0001925. doi: 10.1128/aac.00019.
    >> Share

  37. SZEL V, Phelan JE, Georghiou SB, Dolinger DL, et al
    The ahpC c-54t compensatory mutation is not always a valid surrogate for isoniazid resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2025 Apr 22:e0026525. doi: 10.1128/aac.00265.
    >> Share

  38. ARDIZZONI E, Mulders W, De Diego Fuertes M, Hayrapetyan A, et al
    Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis-experiences from Armenia.
    Antimicrob Agents Chemother. 2025 Apr 9:e0183924. doi: 10.1128/aac.01839.
    >> Share

  39. SAWE S, Tsirizani L, Court R, Gausi K, et al
    The effect of pregnancy on the population pharmacokinetics of levofloxacin in South Africans with rifampicin-resistant tuberculosis.
    Antimicrob Agents Chemother. 2025 Apr 1:e0162624. doi: 10.1128/aac.01626.
    >> Share

    March 2025
  40. PEROUTKA-BIGUS N, Brooks EJ, Ramey ME, D'Erasmo H, et al
    Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy- or hard-to-treat tuberculosis disease.
    Antimicrob Agents Chemother. 2025 Mar 26:e0190124. doi: 10.1128/aac.01901.
    >> Share

  41. VEVE MP, Kenney RM, Aljundi AM, Dierker MS, et al
    Multicenter, retrospective cohort study of antimycobacterial treatment-related harms among patients with non-tuberculosis Mycobacterium infections in the United States.
    Antimicrob Agents Chemother. 2025 Mar 4:e0159624. doi: 10.1128/aac.01596.
    >> Share

    February 2025
  42. GHEBREKRISTOS Y, Ahmed A, Beylis N, Singh S, et al
    Xpert MTB/RIF Ultra-resistant and MTBDRplus-susceptible rifampicin results in people with tuberculosis: utility of FluoroType MTBDR and deep sequencing.
    Antimicrob Agents Chemother. 2025 Feb 7:e0167124. doi: 10.1128/aac.01671.
    >> Share

    January 2025
  43. WYNN EA, Dide-Agossou C, Al Mubarak R, Rossmassler K, et al
    Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during prolonged treatment of mice.
    Antimicrob Agents Chemother. 2025 Jan 17:e0131024. doi: 10.1128/aac.01310.
    >> Share

  44. VOGENSEN VB, Singh S, Allende CJ, Engelthaler DM, et al
    Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosis.
    Antimicrob Agents Chemother. 2025 Jan 16:e0108424. doi: 10.1128/aac.01084.
    >> Share

    December 2024
  45. NDZAMBA B, Denti P, McIlleron H, Smith P, et al
    Pharmacokinetics of ethambutol and weight banded dosing in South African adults newly diagnosed with tuberculosis and HIV.
    Antimicrob Agents Chemother. 2024 Dec 23:e0120024. doi: 10.1128/aac.01200.
    >> Share

  46. MANSJO M, Espinosa-Gongora C, Samanci I, Groenheit R, et al
    Performance of a broth microdilution assay for routine minimum inhibitory concentration determination of 14 anti-tuberculous drugs against the Mycobacterium tuberculosis complex based on the EUCAST reference protocol.
    Antimicrob Agents Chemother. 2024 Dec 18:e0094624. doi: 10.1128/aac.00946.
    >> Share

  47. KOMM OD, Tyagi S, Garcia A, Almeida D, et al
    Contribution of telacebec to novel drug regimens in a murine tuberculosis model.
    Antimicrob Agents Chemother. 2024 Dec 9:e0096224. doi: 10.1128/aac.00962.
    >> Share

    November 2024
  48. VOCAT A, Luraschi-Eggemann A, Antoni C, Cathomen G, et al
    Real-time evaluation of macozinone activity against Mycobacterium tuberculosis through bacterial nanomotion analysis.
    Antimicrob Agents Chemother. 2024 Nov 27:e0131824. doi: 10.1128/aac.01318.
    >> Share

    October 2024
  49. SNOBRE J, Meehan CJ, Mulders W, Rigouts L, et al
    Frameshift mutations in the mmpR5 gene can have a bedaquiline-susceptible phenotype by retaining a protein structure and function similar to wild-type Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2024 Oct 24:e0085424. doi: 10.1128/aac.00854.
    >> Share

  50. MAITRE T, Godmer A, Mory C, Chauffour A, et al
    Levofloxacin activity at increasing doses in a murine model of fluoroquinolone-susceptible and -resistant tuberculosis.
    Antimicrob Agents Chemother. 2024 Oct 16:e0058324. doi: 10.1128/aac.00583.
    >> Share

  51. GOH JJN, Wang Q, Zhang N, de Castro Suarez N, et al
    Prospectively predicting BPaMZ phase IIb/III trial outcomes using a translational mouse-to-human platform.
    Antimicrob Agents Chemother. 2024;68:e0061524.
    >> Share

    September 2024
  52. ENCINAS L, Li S-Y, Rullas-Trincado J, Tasneen R, et al
    Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis.
    Antimicrob Agents Chemother. 2024 Sep 30:e0035724. doi: 10.1128/aac.00357.
    >> Share

  53. BAUMAN AA, Sarathy JP, Kaya F, Massoudi LM, et al
    Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis.
    Antimicrob Agents Chemother. 2024 Sep 30:e0071624. doi: 10.1128/aac.00716.
    >> Share

  54. ALLEN R, Ames L, Baldin VP, Butts A, et al
    An arylsulfonamide that targets cell wall biosynthesis in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2024 Sep 26:e0103724. doi: 10.1128/aac.01037.
    >> Share

  55. POONAWALA H, Zhang Y, Kuchibhotla S, Green AG, et al
    Erratum for Poonawala et al., "Transcriptomic responses to antibiotic exposure in Mycobacterium tuberculosis".
    Antimicrob Agents Chemother. 2024 Sep 19:e0135424. doi: 10.1128/aac.01354.
    >> Share

    August 2024
  56. MARTINI MC, Alonso MN, Cafiero JH, Xiao J, et al
    Loss of glycerol catabolism confers carbon-source-dependent artemisinin resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2024 Aug 28:e0064524. doi: 10.1128/aac.00645.
    >> Share

    July 2024
  57. ROBERTS AH, Moon CW, Faulkner V, Kendall SL, et al
    EfpA is required for regrowth of Mycobacterium tuberculosis following isoniazid exposure.
    Antimicrob Agents Chemother. 2024 Jul 22:e0026124. doi: 10.1128/aac.00261.
    >> Share

  58. SEMERE GEBREYESUS M, Wasmann RE, McIlleron H, Oladokun R, et al
    Population pharmacokinetics of rifabutin among HIV/TB co-infected children on lopinavir/ritonavir-based antiretroviral therapy.
    Antimicrob Agents Chemother. 2024 Jul 22:e0035424. doi: 10.1128/aac.00354.
    >> Share

  59. WASSERMAN S, Antilus-Sainte R, Abdelgawad N, Odjourian NM, et al
    Rifabutin central nervous system concentrations in a rabbit model of tuberculous meningitis.
    Antimicrob Agents Chemother. 2024 Jul 19:e0078324. doi: 10.1128/aac.00783.
    >> Share

  60. SIMEON S, Garcia-Cremades M, Savic R, Solans BP, et al
    Pharmacokinetic-pharmacodynamic modeling of tuberculosis time to positivity and colony-forming unit to assess the response to dose-ranging linezolid.
    Antimicrob Agents Chemother. 2024 Jul 17:e0019024. doi: 10.1128/aac.00190.
    >> Share

    June 2024
  61. KURTZHALS ML, Norman A, Svensson E, Lillebaek T, et al
    Applying whole genome sequencing to predict phenotypic drug resistance in Mycobacterium tuberculosis: leveraging 20 years of nationwide data from Denmark.
    Antimicrob Agents Chemother. 2024 Jun 21:e0043024. doi: 10.1128/aac.00430.
    >> Share

  62. MOTTA I, Cusinato M, Ludman AJ, Lachenal N, et al
    How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
    Antimicrob Agents Chemother. 2024 Jun 6:e0053624. doi: 10.1128/aac.00536.
    >> Share

  63. NEGATU DA, Aragaw WW, Dartois V, Dick T, et al
    A pairwise approach to revitalize beta-lactams for the treatment of TB.
    Antimicrob Agents Chemother. 2024;68:e0003424.
    >> Share

  64. WALSH KF, Lee MH, Zainabadi K, Vilbrun SC, et al
    High variance in quantification of Mycobacterium tuberculosis at low bacterial loads and with differentially detectable mycobacteria.
    Antimicrob Agents Chemother. 2024 Jun 3:e0160123. doi: 10.1128/aac.01601.
    >> Share

    May 2024
  65. YU W, Ju Y, Han X, Tian X, et al
    Bactericidal and sterilizing activity of sudapyridine-clofazimine-TB47 combined with linezolid or pyrazinamide in a murine model of tuberculosis.
    Antimicrob Agents Chemother. 2024 May 1:e0012424. doi: 10.1128/aac.00124.
    >> Share

    April 2024
  66. KENGO A, Nabeemeeah F, Denti P, Sabet R, et al
    Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2024 Apr 10:e0158323. doi: 10.1128/aac.01583.
    >> Share

  67. POONAWALA H, Zhang Y, Kuchibhotla S, Green AG, et al
    Transcriptomic responses to antibiotic exposure in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2024 Apr 8:e0118523. doi: 10.1128/aac.01185.
    >> Share

    March 2024
  68. LYONS MA, Obregon-Henao A, Ramey ME, Bauman AA, et al
    Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis.
    Antimicrob Agents Chemother. 2024 Mar 19:e0101023. doi: 10.1128/aac.01010.
    >> Share

  69. VILLELLAS C, Stevenaert F, Remmerie B, Andries K, et al
    Sub-MIC levels of bedaquiline and clofazimine can select Mycobacterium tuberculosis mutants with increased MIC.
    Antimicrob Agents Chemother. 2024 Mar 12:e0127523. doi: 10.1128/aac.01275.
    >> Share

    February 2024
  70. OLIVENCA F, Pires D, Silveiro C, Gama B, et al
    Ethambutol and meropenem/clavulanate synergy promotes enhanced extracellular and intracellular killing of Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2024 Feb 27:e0158623. doi: 10.1128/aac.01586.
    >> Share

  71. LI S-Y, Tyagi S, Soni H, Betoudji F, et al
    Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis.
    Antimicrob Agents Chemother. 2024 Feb 20:e0156223. doi: 10.1128/aac.01562.
    >> Share

    January 2024
  72. SINGH P, Kumar A, Sharma P, Chugh S, et al
    Identification and optimization of pyridine carboxamide-based scaffold as a drug lead for Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2024 Jan 9:e0076623. doi: 10.1128/aac.00766.
    >> Share

    December 2023
  73. RUELAS CASTILLO J, Neupane P, Karanika S, Krug S, et al
    The heme oxygenase-1 metalloporphyrin inhibitor stannsoporfin enhances the bactericidal activity of a novel regimen for multidrug-resistant tuberculosis in a murine model.
    Antimicrob Agents Chemother. 2023 Dec 22:e0104323. doi: 10.1128/aac.01043.
    >> Share

  74. SINGH S, Gumbo T, Boorgula GD, Thomas TA, et al
    Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant Mycobacterium tuberculosis in the hollow fiber system model.
    Antimicrob Agents Chemother. 2023 Dec 22:e0108023. doi: 10.1128/aac.01080.
    >> Share

  75. ALI AM, P Solans B, Hesseling AC, Winckler J, et al
    Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosis.
    Antimicrob Agents Chemother. 2023 Dec 19:e0079423. doi: 10.1128/aac.00794.
    >> Share

  76. PANDEY S, Vilcheze C, Werngren J, Bainomugisa A, et al
    Loss-of-function mutations in ndh do not confer delamanid, ethionamide, isoniazid, or pretomanid resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2023 Dec 1:e0109623. doi: 10.1128/aac.01096.
    >> Share

    November 2023
  77. VAN DER LAAN LE, Garcia-Prats AJ, McIlleron H, Abdelwahab MT, et al
    Optimizing dosing of the cycloserine pro-drug terizidone in children with rifampicin-resistant tuberculosis.
    Antimicrob Agents Chemother. 2023 Nov 16:e0061123. doi: 10.1128/aac.00611.
    >> Share

  78. ALMEIDA D, Li S-Y, Lee J, Hafkin B, et al
    Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis.
    Antimicrob Agents Chemother. 2023 Nov 15:e0078923. doi: 10.1128/aac.00789.
    >> Share

  79. LANNI F, Antilus Sainte R, Hansen M Jr, Parigi P, et al
    A preclinical model of TB meningitis to determine drug penetration and activity at the sites of disease.
    Antimicrob Agents Chemother. 2023 Nov 15:e0067123. doi: 10.1128/aac.00671.
    >> Share

    October 2023
  80. VAN SCHALKWYK M, Bekker A, Decloedt E, Wang J, et al
    Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s.
    Antimicrob Agents Chemother. 2023 Oct 26:e0073723. doi: 10.1128/aac.00737.
    >> Share

  81. XIE YL, Modi N, Handler D, Yu S, et al
    Simplified urine-based method to detect rifampin underexposure in adults with tuberculosis: a prospective diagnostic accuracy study.
    Antimicrob Agents Chemother. 2023 Oct 25:e0093223. doi: 10.1128/aac.00932.
    >> Share

  82. KENGO A, Nabisere R, Gausi K, Musaazi J, et al
    Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin.
    Antimicrob Agents Chemother. 2023 Oct 18:e0043023. doi: 10.1128/aac.00430.
    >> Share

  83. KENGO A, Gausi K, Nabisere R, Musaazi J, et al
    Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin.
    Antimicrob Agents Chemother. 2023 Oct 18:e0043123. doi: 10.1128/aac.00431.
    >> Share

  84. RAMEY ME, Kaya F, Bauman AA, Massoudi LM, et al
    Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis model.
    Antimicrob Agents Chemother. 2023 Oct 4:e0059723. doi: 10.1128/aac.00597.
    >> Share

    September 2023
  85. STEMKENS R, Jager V, Dawson R, Diacon AH, et al
    Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
    Antimicrob Agents Chemother. 2023 Sep 28:e0068323. doi: 10.1128/aac.00683.
    >> Share

  86. MEIKLE V, Zhang L, Niederweis M
    Intricate link between siderophore secretion and drug efflux in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2023 Sep 7:e0162922. doi: 10.1128/aac.01629.
    >> Share

    August 2023
  87. WALTER ND, Ernest JP, Dide-Agossou C, Bauman AA, et al
    Lung microenvironments harbor Mycobacterium tuberculosis phenotypes with distinct treatment responses.
    Antimicrob Agents Chemother. 2023 Aug 11:e0028423. doi: 10.1128/aac.00284.
    >> Share

    June 2023
  88. ALI AM, Radtke KK, Hesseling AC, Winckler J, et al
    QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies.
    Antimicrob Agents Chemother. 2023 Jun 26:e0144822. doi: 10.1128/aac.01448.
    >> Share

  89. GRIES R, Dal Molin M, Chhen J, van Gumpel E, et al
    Characterization of Two Novel Inhibitors of the Mycobacterium tuberculosis Cytochrome bc(1) Complex.
    Antimicrob Agents Chemother. 2023 Jun 26:e0025123. doi: 10.1128/aac.00251.
    >> Share

  90. VAN DER LAAN LE, Garcia-Prats AJ, Schaaf HS, Chirehwa M, et al
    Erratum for van der Laan et al., "Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis".
    Antimicrob Agents Chemother. 2023 Jun 20:e0072023. doi: 10.1128/aac.00720.
    >> Share

  91. CHANG YS, Li SY, Pertinez H, Betoudji F, et al
    Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy.
    Antimicrob Agents Chemother. 2023 Jun 14:e0048123. doi: 10.1128/aac.00481.
    >> Share

    May 2023
  92. XU J, Li D, Shi J, Wang B, et al
    Bedquiline Resistance Mutations: Correlations with Drug Exposures and Impact on the Proteome in M. tuberculosis.
    Antimicrob Agents Chemother. 2023 May 31:e0153222. doi: 10.1128/aac.01532.
    >> Share

  93. DAWSON R, Diacon AH, Narunsky K, De Jager VR, et al
    Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832.
    Antimicrob Agents Chemother. 2023 May 23:e0147722. doi: 10.1128/aac.01477.
    >> Share

  94. MATHIYAZAKAN V, Wong CF, Harikishore A, Pethe K, et al
    Cryo-Electron Microscopy Structure of the Mycobacterium tuberculosis Cytochrome bcc:aa(3) Supercomplex and a Novel Inhibitor Targeting Subunit Cytochrome cI.
    Antimicrob Agents Chemother. 2023 May 9:e0153122. doi: 10.1128/aac.01531.
    >> Share

    April 2023
  95. ZHU Y, Zhu L, Davies Forsman L, Paues J, et al
    Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens.
    Antimicrob Agents Chemother. 2023 Apr 25:e0170022. doi: 10.1128/aac.01700.
    >> Share

  96. NEGATU DA, Aragaw WW, Cangialosi J, Dartois V, et al
    Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections.
    Antimicrob Agents Chemother. 2023;67:e0165522.
    >> Share

  97. LIU Y, Moodley M, Pasipanodya JG, Gumbo T, et al
    Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments.
    Antimicrob Agents Chemother. 2023;67:e0140122.
    >> Share

    March 2023
  98. ECKHARDT E, Li Y, Mamerow S, Schinkothe J, et al
    Pharmacokinetics and Efficacy of the Benzothiazinone BTZ-043 against Tuberculous Mycobacteria inside Granulomas in the Guinea Pig Model.
    Antimicrob Agents Chemother. 2023 Mar 28:e0143822. doi: 10.1128/aac.01438.
    >> Share

  99. LI SY, Converse PJ, Betoudji F, Lee J, et al
    Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model.
    Antimicrob Agents Chemother. 2023 Mar 15:e0003523. doi: 10.1128/aac.00035.
    >> Share

  100. ISMAIL N, Dippenaar A, Warren RM, Peters RPH, et al
    Emergence of Canonical and Noncanonical Genomic Variants following In Vitro Exposure of Clinical Mycobacterium tuberculosis Strains to Bedaquiline or Clofazimine.
    Antimicrob Agents Chemother. 2023 Mar 9:e0136822. doi: 10.1128/aac.01368.
    >> Share

    February 2023
  101. ABDELGAWAD N, Tshavhungwe MP, Rohlwink U, McIlleron H, et al
    Population Pharmacokinetic Analysis of Rifampicin in Plasma, Cerebrospinal Fluid, and Brain Extracellular Fluid in South African Children with Tuberculous Meningitis.
    Antimicrob Agents Chemother. 2023 Feb 23:e0147422. doi: 10.1128/aac.01474.
    >> Share

  102. CHIREHWA MT, Resendiz-Galvan JE, Court R, De Kock M, et al
    Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling.
    Antimicrob Agents Chemother. 2023 Feb 6:e0142622. doi: 10.1128/aac.01426.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016